U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C86H97Cl3N10O26
Molecular Weight 1793.1039
Optical Activity UNSPECIFIED
Defined Stereocenters 22 / 22
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ORITAVANCIN

SMILES

CC(C)C[C@]([H])(C(=N[C@]1([H])[C@@]([H])(c2ccc(c(c2)Cl)Oc3cc4cc(c3O[C@@]5([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(CO)O5)O)O)O[C@@]6([H])C[C@@](C)([C@]([H])([C@]([H])(C)O6)O)NCc7ccc(cc7)-c8ccc(cc8)Cl)Oc9ccc(cc9Cl)[C@]([H])([C@@]%10([H])C(=N[C@@]([H])(c%11cc(cc(c%11-c%12cc(ccc%12O)[C@]([H])(C(=N%10)O)N=C([C@]4([H])N=C([C@]([H])(CC(=N)O)N=C1O)O)O)O)O)C(=O)O)O)O[C@@]%13([H])C[C@@](C)([C@]([H])([C@]([H])(C)O%13)O)N)O)O)NC

InChI

InChIKey=VHFGEBVPHAGQPI-LXKZPTCJSA-N
InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB04911 | https://www.ncbi.nlm.nih.gov/pubmed/26831328

Oritavancin is an glycopeptide antibiotic with bactericidal activity effective in treating infections caused by Gram-positive organisms. It treats complicated skin and skin structure infections. This drug demonstrates similar activity to vancomycin, but it has stronger activity against Staphylococcus and Enterococcus. The pharmacokinetics and pharmacodynamics of oritavancin appear to be favourable and once-daily dosing is likely. The incidence of multi-drug resistant bacteria is increasing and explorations into additional treatment options are essential. Oritavancin is marketed under the brand name Orbactiv. Orbactiv is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. Oritavancin has the following mechanism of action: 1) Inhibition of the transglycosylation (polymerisation) step of cell wall biosynthesis by binding to the stem peptide of peptidoglycan precursors 2) Inhibition of the transpeptidation (crosslinking) step of cell wall biosynthesis by binding to the peptide bridging segments of the cell wall 3) Disruption of bacterial membrane integrity, leading to depolarisation, increased permeability and rapid cell death.

CNS Activity

Curator's Comment:: Oritavancin has limited penetration through the blood-brain barrier and subsequent low levels in CSF

Originator

Curator's Comment:: # Eli Lilly

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ORBACTIV

Approved Use

ORBACTIV is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.2) 1.1 Acute Bacterial Skin and Skin Structure Infections ORBACTIV® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin–resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.40728323E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
138 μg/mL
1200 mg single, intravenous
dose: 1200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
[NO STEREO] ORITAVANCIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2800 μg × h/mL
1200 mg single, intravenous
dose: 1200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
[NO STEREO] ORITAVANCIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.4 h
1200 mg single, intravenous
dose: 1200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
[NO STEREO] ORITAVANCIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
15%
1200 mg single, intravenous
dose: 1200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
[NO STEREO] ORITAVANCIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg single, intravenous
Recommended
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources: Page: 5
unhealthy, 18-89 years
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: 18-89 years
Sex: M+F
Population Size: 976
Sources: Page: 5
Disc. AE: Cellulitis, Osteomyelitis...
AEs leading to
discontinuation/dose reduction:
Cellulitis (0.4%)
Osteomyelitis (0.3%)
Sources: Page: 5
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Disc. AE: Mouth ulceration, Nausea...
AEs leading to
discontinuation/dose reduction:
Mouth ulceration (1 patient)
Nausea (1 patient)
Rectal haemorrhage (1 patient)
Vomiting (1 patient)
Chest discomfort (1 patient)
Infusion site extravasation (1 patient)
Infusion site pain (1 patient)
Infusion site phlebitis (2 patients)
Infusion site thrombosis (1 patient)
Sources: Page: 111
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Disc. AE: Drug hypersensitivity, Urine ketone body present...
AEs leading to
discontinuation/dose reduction:
Drug hypersensitivity (1 patient)
Urine ketone body present (1 patient)
Hyperglycaemia (1 patient)
Tenosynovitis (1 patient)
Somnolence (1 patient)
Erythema multiforme (1 patient)
Leukocytoclastic vasculitis (1 patient)
Pruritus (2 patients)
Rash (1 patient)
Rash macular (1 patient)
Urticaria (1 patient)
Hypotension (1 patient)
Sources: Page: 112
AEs

AEs

AESignificanceDosePopulation
Osteomyelitis 0.3%
Disc. AE
1200 mg single, intravenous
Recommended
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources: Page: 5
unhealthy, 18-89 years
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: 18-89 years
Sex: M+F
Population Size: 976
Sources: Page: 5
Cellulitis 0.4%
Disc. AE
1200 mg single, intravenous
Recommended
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources: Page: 5
unhealthy, 18-89 years
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: 18-89 years
Sex: M+F
Population Size: 976
Sources: Page: 5
Chest discomfort 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Infusion site extravasation 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Infusion site pain 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Infusion site thrombosis 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Mouth ulceration 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Nausea 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Rectal haemorrhage 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Vomiting 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Infusion site phlebitis 2 patients
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 111
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 111
Drug hypersensitivity 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Erythema multiforme 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Hyperglycaemia 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Hypotension 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Leukocytoclastic vasculitis 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Rash macular 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Rash 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Somnolence 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Tenosynovitis 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Urine ketone body present 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Urticaria 1 patient
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Pruritus 2 patients
Disc. AE
1200 mg 1 times / day multiple, intravenous (median)
Recommended
Dose: 1200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 1 times / day
Sources: Page: 112
unhealthy, adult
n = 976
Health Status: unhealthy
Condition: acute bacterial skin
Age Group: adult
Sex: M+F
Population Size: 976
Sources: Page: 112
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
weak
yes (co-administration study)
Comment: The effect of oritavancin on omeprazole, a CYP2C19 substrate, was determined from the omeprazole/5-OH omeprazole ratio in the plasma at 2 hours. There was an increase of 15% in this metabolic ratio. The Day 1/Day-4 geometric mean ratio (point estimate) and 90% CI was 1.155 (0.957, 1.395), suggesting that oritavancin may be a weak inhibitor of CYP2C19.
Page: 40.0
weak
yes (co-administration study)
Comment: In the overall population (N=16), plasma Swarfarin AUC0-inf values increased by 31%. The Day 1/Day-4 geometric mean ratio (point estimate) and 90% CI was 1.319 (1.294, 1.345).
Page: 40.0
yes [IC50 16 uM]
yes [IC50 40.5 uM]
yes
yes
yes
yes (co-administration study)
Comment: The effect of oritavancin on dextromethorphan, a CYP2D6 substrate, was determined from the dextromethorphan over dextrorphan molar ratio in urine samples collected over a 12-hour interval after dosing. The Day 1/Day -4 geometric mean ratio (point estimate) and 90% CI (N=13 subjects) was 0.692 (0.431, 1.110). These findings indicate a 31% decrease in the urinary dextromethorphan/dextrorphan ratio, and that oritavancin is a weak inducer of CYP2D6.
Page: 40.0
yes
yes (co-administration study)
Comment: In the presence of oritavancin (Day 1) the AUC0-inf of midazolam was decreased by 18% and the CL/F was increased by 24%. The Day 1/Day -4 geometric mean ratio (point estimate) and 90% CI for CL/F was 1.239 (1.135, 1.353). The 24% increase in the midazolam CL/F and decrease (18%) in the midazolam AUC0-inf indicates that oritavancin is a weak inducer of CYP3A4.
Page: 40.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.
2009 Apr
Patents

Sample Use Guides

A 1200 mg single dose is administered by intravenous infusion over 3 hours.
Route of Administration: Intravenous
The MIC50 and MIC90 for oritavancin against vancomycin-susceptible E. faecalis were 0.015 and 0.03 mg/L and E. faecium of
Name Type Language
ORITAVANCIN
INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
LY-333328
Code English
ORITAVANCIN [WHO-DD]
Common Name English
(4''R)-22-O-(3-AMINO-2,3,6-TRIDEOXY-3-C-METHYL-.ALPHA.-L-ARABINO-HEXOPYRANOSYL)-N(SUP 3)''-(P-(P-CHLOROPHENYL)BENZYL)VANCOMYCIN
Common Name English
ORITAVANCIN [INN]
Common Name English
VANCOMYCIN, 22-O-(3-AMINO-2,3,6-TRIDEOXY-3-C-METHYL-.ALPHA.-L-ARABINO-HEXOPYRANOSYL)-N3''-((4'-CHLORO(1,1'-BIPHENYL)-4-YL)METHYL)-, (4''R)-
Systematic Name English
ORITAVANCIN [MART.]
Common Name English
ORITAVANCIN [VANDF]
Common Name English
LY333328
Code English
ORITAVANCIN [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ01XA05
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
NDF-RT N0000191281
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
WHO-ATC J01XA05
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
Code System Code Type Description
NDF-RT
N0000191280
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY Lipoglycopeptides [Chemical/Ingredient]
EVMPD
SUB28422
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
DRUG CENTRAL
4678
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
NDF-RT
N0000185506
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY Cytochrome P450 3A4 Inducers [MoA]
PUBCHEM
16136912
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
RXCUI
1547611
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
ORITAVANCIN
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
NDF-RT
N0000191267
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY Cytochrome P450 2D6 Inducers [MoA]
DRUG BANK
DB04911
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
INN
7979
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
NDF-RT
N0000185504
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
NCI_THESAURUS
C174855
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
MERCK INDEX
M8233
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY Merck Index
CAS
171099-57-3
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
ChEMBL
CHEMBL1688530
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
FDA UNII
PUG62FRZ2E
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY
NDF-RT
N0000182140
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
LACTMED
Oritavancin
Created by admin on Sat Jun 26 01:43:17 UTC 2021 , Edited by admin on Sat Jun 26 01:43:17 UTC 2021
PRIMARY